Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Por um escritor misterioso
Descrição
Dupilumab pharmacokinetics and effect on type 2 biomarkers in
Dupilumab reduces attacks and improves lung function in asthmatic
Dupilumab in the management of moderate-to-severe asthma: the data
Dupilumab in children aged 6 months to younger than 6 years with
How DUPIXENT® (dupilumab) is Taken: Asthma Dosing
New monoclonal antibody shows promise for severe asthma
Dupixent® (dupilumab injection) now approved in Canada for the
CHMP recommends approval of Dupixent® (dupilumab) for children
Frontiers Dupilumab efficacy and safety in patients with
Dupilumab leads to better-controlled asthma and quality of life in
DUPIXENT® (dupilumab) Dosage & Administration Information
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic
International study supports dupilumab for treatment of moderate
DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis
Dupixent® reduces rate of severe asthma attacks in children, finds
de
por adulto (o preço varia de acordo com o tamanho do grupo)
